ECDC - Risk assessments

ECDC assessed the risk to the EU/EEA of the presence and the possible transmission of prions, which have been linked to to Creutzfeldt-Jakob disease, by blood and plasma-derived medicinal products (PDMPs) manufactured from donations obtained in the UK.

Extreme rainfall on 14 and 15 July 2021 and subsequent flooding in Western Europe has taken a high number of human lives and caused substantial damage to community infrastructure and the environment. This rapid risk assessment focuses on the most common infectious diseases and health risks associated with flood-affected areas, taking into account evidence from previous similar events in Europe.

Coronavirus disease (COVID-19) outbreaks in long-term care facilities (LTCFs) in European Union and European Economic Area (EU/EEA) countries have caused significant morbidity and mortality since the beginning of the COVID-19 pandemic.

Between 15 March and 6 July 2021, 348 confirmed S. Braenderup sequence type 22 (ST22) cases were reported in 12 European Union/European Economic Area (EU/EEA) countries and the United Kingdom (UK).

Rapid risk/outbreaks assessment aim at supporting the countries and the European Commission in their preparedness and response to a public health threat. They provide a timely summary and risk assessment of a public health threat for EU/EEA countries related to a specific event. They also include potential options for response. As outbreaks or public health events develop, ECDC may issue updated risk assessments.

The aim of this threat assessment brief is to assess potential public health implications of the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) for the European Union and European Economic Area (EU/EEA).

This report assesses SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA.